# Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

> **NCT07431281** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 2130 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Cancer

## Interventions

- **DRUG:** Sonesitatug vedotin
- **DRUG:** Rilvegostomig
- **DRUG:** Nivolumab
- **DRUG:** Capecitabine
- **DRUG:** 5-Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Zolbetuximab
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT07431281
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-03
- **Primary completion:** 2029-08-16
- **Final completion:** 2031-10-27
- **Target enrollment:** 2130 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07431281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07431281, "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07431281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*